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Highlights 
▪ A new approach was used to find the functional enhancers of the Tgm2 gene in apoptotic 
thymocytes 
▪ DNase-seq and ChIP-seq results from the ENCODE data base were integrated to map 
putative enhancers 
▪ Then their eRNA levels were determined in thymocytes exposed to signals known to 
regulate TGM2 expression 
▪ Their transcription factor recruitment was simultaneously determined by ChIP-qPCR 
▪ Retinoids, TGF-β and dbcAMP selectively activate enhancers at the Tgm2 locus 
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Abstract 
Transglutaminase 2 (TGM2) is a ubiquitously expressed multifunctional protein, which 
participates in various biological processes including thymocyte apoptosis. As a result, the 
transcriptional regulation of the gene is complex and must depend on the cell type. Previous 
studies from our laboratory have shown that in dying thymocytes the expression of TGM2 is 
induced by external signals derived from engulfing macrophages, such as retinoids, 
transforming growth factor (TGF)-and adenosine, the latter triggering the adenylate cyclase 
signaling pathway. The existence of TGF-and retinoid responsive elements in the promoter 
region of Tgm2 has already been reported, but the intergenic regulatory elements participating 
in the regulation of Tgm2 have not yet been identified. Here we used publicly available results 
from DNase I hypersensitivity analysis followed by deep sequencing and chromatin 
immunoprecipitation followed by deep sequencing against CCCTC-binding factor, 
H3K4me3, H3K4me1 and H3K27ac to map a putative regulatory element set for Tgm2 in 
thymocytes. By measuring eRNA expressions of these putative enhancers in retinoid, rTGF- 
or dibutiryl cAMP-exposed thymocytes we determined which of them are functional. By 
applying ChIP-qPCR against SMAD4, retinoic acid receptor, retinoid X receptor, cAMP 
response element binding protein, P300 and H3K27ac under the same conditions, we 
identified two enhancers of Tgm2, which seem to act as integrators of the TGF-, retinoid and 
adenylate cyclase signaling pathways in dying thymocytes. Our study describes a novel 
strategy to identify and characterize the signal specific functional enhancer set of a gene by 
integrating genome-wide datasets and measuring the production of enhancer specific RNA 
molecules.  
 
Key words:  T cells, Apoptosis, Gene Regulation, Enhancer RNA, Transglutaminase 2, ChIP-
seq 
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1. Introduction 
Transglutaminases [1] are a family of thiol- and Ca2+-dependent acyl transferases that 
catalyze the formation of a covalent bond between thecarboxamide groups of peptide-
bound glutamine residues and various primary amines, including the amino group of lysine 
in certain proteins. The reaction results in post-translational modification of proteins by 
establishing glutamyl)lysine cross-linkages and/or covalent incorporation of mono- or 
polyamines and into proteins. Transglutaminase 2 (TGM2) is very unique in the 
transglutaminase family, because besides being a transglutaminase it also possesses GTPase, 
protein disulphide isomerase and protein kinase enzymatic activities. In addition, TGM2 can 
also function in various biological settings as a protein/protein interaction partner [2]. TGM2 
has been known for a long time to be associated with the in vivo apoptosis program of various 
cell types including T cells [3]. TGM2 expression is induced in thymocytes dying in vivo 
following exposure to various apoptotic signals [4], and TGM2 also appears in the dying T 
lymphocytes of HIV-infected individuals [5]. While, however, TGM2 is strongly induced in 
dying thymocytes in vivo, no induction of TGM2 was observed, when thymocytes were 
induced to die by the same stimuli in vitro [6] indicating that signals arriving from the tissue 
environment contribute to the in vivo induction of the enzyme in apoptotic thymocytes. Later 
studies from our laboratory have demonstrated that in dying thymocytes the expression of 
TGM2 is induced by signals derived from engulfing macrophages, such as retinoids [7], 
transforming growth factor (TGF)- [8] and adenosine, the latter triggering the adenylate 
cyclase signaling pathway [9].        
 Due to its ubiquitous appearance and multiple functions, the expression of the Tgm2 
gene must be tightly controlled. The in vivo appearance of TGM2 protein in dying thymocytes 
seems to be regulated at the level of transcription, since in mice, which carry the beta-
galactosidase reporter gene under the control of a 3.8 kilobase fragment of the Tgm2 
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promoter, the beta-galactosidase expression showed strong correlation with the endogenous 
TGM2 expression [6]. Other studies also indicate that the complex regulation of TGM2 
expression is mediated at the level of transcription. Thus research has led to the identification 
of functional retinoid [10] and TGF- [11] response elements in the promoter region of the 
gene. In addition, response elements for nuclear factorB [12] and the hypoxia inducible 
factor [13] have been also identified in the core promoter. The limitation of these studies was 
that they could focus only on the promoter element at that time.     
 Recent advances in sequencing technologies allow genome-wide mapping of all the 
intergenic regulatory elements including enhancers. The combination of the DNase I 
hypersensitivity analysis followed by deep sequencing (DNase-seq) and  chromatin 
immunoprecipitation followed by deep sequencing (ChIP-seq) datasets proved to be useful in 
identifying and characterizing the chromatin signatures of enhancer elements [14]. These 
include enrichment of histone 3 lysine 4 monomethylation (H3K4me1) as compared to 
H3K4me3, which peaks at promoter elements [15]. However, enhancers exhibiting these 
modifications are not necessary functional, because most of the open regulatory elements are 
enriched for at least one of these markers. Functional enhancers are rather associated with 
histone 3 acetylated at lysine 27 (H3K27ac) [16], with the transcription co-regulators P300 or 
CREB binding protein (CBP) [17], and with the actively transcribing polymerase II (RNAPII) 
[18]. The appearance of RNA sequencing and Global Run-On sequencing (GRO-seq) 
technologies revealed the existence of new types of RNA species including enhancer RNAs 
(eRNAs) [19,20]. These short RNAs are transcribed from active enhancers only and follow 
the induction profile of their target genes. Recently, it has been shown that the modified 
version of GRO-seq by enriching 5’-capped RNAs is a very powerful tool to identify active 
transcriptional regulatory elements based on its improved eRNA detection ability. The 
analysis of such datasets demonstrated the enrichment of expression quantitative trait loci, 
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disease-associated polymorphisms, H3K27ac and transcription factor binding sites at 
transcriptionally active regulatory elements [21]. According to these findings, eRNAs 
represent an accepted functional enhancer feature [22]. Hence, it has already been exploited to 
assign the active enhancer element repertoire of certain transcription factors, such as ESR1 
[23] or RXR [24] to their target genes genome-wide.     
 Increasing evidence suggests that genes and their enhancers are located in functional 
domains separated from each other by proteins bound to insulator sequences. Insulators 
provide a barrier function to prevent repressive heterochromatin from spreading into a 
neighboring domain, provide an enhancer-blocking function when positioned between the 
enhancer and promoter, and allow three-dimensional looping of genomic regions [25,26]. 
CCCTC-binding factor (CTCF) is known to act as an insulator, but also implicated in the 
regulation of higher order chromatin structure. Recent studies investigating the spatial 
organization of the genome show that the direction of the CTCF motif determines the 3D 
folding of the genome [27]. In addition, it has been also shown that CTCF anchors play a vital 
role in connecting enhancers to their target gene promoter [28].    
 Based on advanced sequencing technologies, in 2014 the ENCODE (Encyclopedia of 
DNA elements) Consortium has released genome-wide datasets of the mouse genome [29]. 
These studies aimed to identify the cis-acting element repertoire of several human and mouse 
cell lines. In addition, they provided genome-wide data also from various mouse tissues. 
 In the present work we decided to identify those enhancers which regulate the 
expression of Tgm2 in dying thymocytes exposed to retinoids, TGF-and/ or following 
activation of the adenylate cyclase signaling pathway. Having access to the ENCODE 
generated datasets from mouse thymus, first we integrated DNase-seq and ChIP-seq results 
against CTCF, H3K4me3, H3K4me1 and H3K27ac in order to map the putative regulatory 
elements participating in the regulation of Tgm2. Then by measuring their basal and induced 
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eRNA levels, we determined which of them are functional. Finally, we analyzed the basal and 
induced binding of SMAD4, retinoic acid (RAR), retinoid X (RXR) receptor and cAMP 
response element binding protein (CREB), transcription factors mediating the effects of the 
retinoid, TGF- and adenylate cyclase signaling pathways, to these enhancers. Our study 
describes the thymocyte specific enhancer elements of Tgm2 and presents a novel strategy to 
identify and characterize the functional contribution of individual enhancers to gene 
regulation.  
 
2. Materials and Methods 
2.1. Materials  
All reagents were obtained from Sigma-Aldrich (Budapest, Hungary) except indicated 
otherwise. 
 
2.2. Experimental animals  
Most of the experiments were carried out with 4-wk-old C57Bl/6 mice. Mice were maintained 
in specific pathogen-free condition in the Central Animal Facility of our university, and all 
animal experiments were approved by the Animal Care and Use Committee of University of 
Debrecen (DEMÁB).  
 
2.3. Thymocyte cultures 
Isolated thymocytes (1x107/ml) were cultured in RPMI medium 1640 supplemented with 10% 
charcoal stripped FBS, 2 mM glutamine, 1 mM Na pyruvate, 100 U/ml penicillin and 100 
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mg/ml streptomycin at 37°C in 5% CO2. Cells were exposed to 0.3 µM 9-cis retinoic acid 
(9cRA) (Tocris Bioscience, Eching, Germany), 1 M AM580, an RAR agonist, nM  
LG268, an RXR agonist analogue alone, or in combination with 100 µM db-cAMP, a cell 
permeable cAMP or with 5 ng/ml recombinant human TGF-β1 (AbD Serotec, Kidlington, 
UK) and for the indicated time periods. 
 
2.4 Real-Time Quantitative PCR (qRT-PCR) for detecting eRNA levels    
For this purpose we designed eRNA specific primer pairs targeting the enhancer sequences 
upstream to their DNase hypersensitive sites, but on the enriched histone modifications 
(Supplementary Fig. 1). We used primer3 software to design the eRNA specific primers with 
standard conditions except the followings: amplicon length: 90-150bp; Tm: 59-60°C [30]. 
RNA was isolated with Trizol Reagent according to the manufacturer’s guidelines. For 
mRNA measurements, High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Budapest, Hungary) was used and transcript quantification was performed by Quantitative 
Real-Time PCR reaction using SYBR green dye (gb SG PCR Master Mix, Generi Biotech, 
Czech Republic). For enhancer RNA measurements, RNA was isolated with the same Trizol 
based method, but samples were digested with DNaseI enzyme for 1 hour at 37C. RNA was 
then reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Budapest, Hungary) and quantification was performed with LightCycler® 480 
SYBR Green I Master (Roche, USA). The following PCR program was used for enhancer 
RNA and mRNA detection: 95°C-3 min; 95°C-30 sec; 60°C-1 min. The last two steps were 
repeated 40 times. Transcript levels were normalized to Ppia. Primer sequences: 
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Tgm2 +30kb eRNA                          
Fw: 5’-CCACTGCAGCCTTCCTAGTT-3’                   
Rev: 5’-TCAGCCAGCACCTCTAGACA-3’ 
Tgm2 -7.9kb eRNA                            
Fw: 5’-CTCTAGGGCCCCAGTTGAG-3’                             
Rev: 5’-CAGGAGAGATGCCCTTCCAG-3’ 
Tgm2 -13kb eRNA                                                 
Fw: 5’-GTGAACTGTGCTGCTGAACA-3’            
Rev: 5’-CAATCTCCAAAGCACCCCAC-3’ 
Tgm2 -20kb eRNA                    
Fw: 5’-AGCCTGAACCCACAAGTGTA-3’                     
Rev: 5’-TGTGTGTGCGTGTGTGTTTT-3’ 
Tgm2 -28kb eRNA                   
Fw: 5’-AGCTTTCCTGACCTGGTGTT-3’                      
Rev: 5’-TGCCTCACCACCATCATCA-3’ 
Prmt8 -1.7kb                 
Fw: 5’-CGTGAGCAGAGGTGAGGAGT-3’                
Rev: 5’-GGTTAACCCAAGCTTCTTGCT-3’ 
 
2.5. Real-Time Quantitative PCR (qRT-PCR) for detecting Tgm2 and Rprd1b mRNA 
levels 
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RNA was isolated with Trizol Reagent according to the manufacturer’s guidelines. For 
mRNA measurements, High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Budapest, Hungary) was used and transcript quantification was performed by qRT-PCR 
reaction using SYBR green dye (gb SG PCR Master Mix, Generi Biotech, Czech Republic). 
RNA was then reverse transcribed using High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Budapest, Hungary) and quantification was performed with 
LightCycler® 480 SYBR Green I Master (Roche, USA).  
Tgm2 
Fw: 5’-AGGACATCAACCTGACCCTG-3’                
Rev: 5’-CTTGATTTCGGGATTCTCCA-3’ 
Rprd1b                          
Fw: 5’-GACGTGTCGCTGCTAGAGAA-3’                                      
Rev: 5’-CCGCTAGTAACAGACATGCTTC-3’ 
 
2.6. Chromatin immunoprecipitation followed by qPCR  
ChIP was performed as previously described [31] with minor modifications. Briefly, cells 
were crosslinked with Di(N-succinimidyl) glutarate (ProteoChem, USA) for 30 minutes and 
then with formaldehyde for 10 min. Crosslinking reaction was terminated by the addition of 
glycine. Chromatin was sonicated with Diagenode Bioruptor to generate 200-1000 bp 
fragments. Immunoprecipitation was performed with antibodies against pre-immune IgG 
(Millipore, 12-370), RXR (sc-774), P300 (sc-585), CBP (sc-369X), CREB1 (ab31387), 
SMAD4 (sc-7154X), H3K27ac (ab4729) from Merck (Budapest, Hungary), Santa Cruz 
Biotechnology (Dallas, USA) or Abcam (Cambridge, UK). Chromatin antibody complexes 
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were precipitated with Protein A-coated paramagnetic beads (Life technologies, USA). After 
6 washing steps complexes were eluted and reverse crosslinked. DNA fragments were column 
purified (Qiagen, MinElute). DNA was diluted and used for qPCR analysis. The following 
primer sequences were used:  
Tgm2 +30kb                           
Fw: 5’-TCTGCCTAAGATGTGCAGAGG-3’                                      
Rev: 5’-CCCTCTCTGAGGCGTTCC-3’ 
Tgm2 -7.9kb                                                       
Fw: 5’-CCAGAATAGAGGAGTGCTGGTAA-3’                          
Rev:5’-CAGTATTTTCTTGGTTGACTGTGG-3’ 
Tgm2 -13kb                                                               
Fw: 5’-GCAGAGTTGGCTCTCGTCA-3’                   
Rev: 5’-GTGTCTGCCTGTCCTGTCTG-3’ 
Tgm2 -20kb                                                                
Fw: 5’-TGGCATACACACAAGGAAGTG-3’                  
Rev: 5’-TTCCTGATCTGGTTTGTCAGTG-3’ 
Tgm2 -28kb                                                   
Fw: 5’-GAAGTCACCCCCAATCTGAG-3’                 
Rev: 5’-ATGCAGGTTTGCTGACTGCT-3’ 
Prmt8 -1.7kb                 
Fw: 5’-CGTGAGCAGAGGTGAGGAGT-3’                
Rev: 5’-GGTTAACCCAAGCTTCTTGCT-3’ 
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2.7. Accession numbers for ChIP-seq experiments  
ChIP-seq experiments performed by the ENCODE Consortium have been downloaded and 
visualized by the Integrative Genomics Viewer (IGV) genome browser [32]. More 
specifically, ChIP-seq datasets were used against CTCF (GSM918734), H3K4me3 
(GSM1000101), H3K4me1 (GSM1000102) and H3K27ac (GSM1000103). In addition 
DNaseI-seq results were also used (GSM1003827). 
 
2.8. Chromosome conformation capture (3C) 
Chromosome conformation capture experiments were carried out essentially as described 
previously [33,34]. Briefly, thymocytes were isolated and cross-linked using 2% 
formaldehyde for 10 min. Cross-linking reaction was quenched with glycine and nuclei were 
isolated. Chromatin was digested with HindIII restriction enzyme overnight at 37°C. On the 
following day digested chromatin was ligated in the presence of T4 DNA ligase (50U) at 
16°C for 16 h. Ligated DNA fragments were isolated by phenol:chloroform extraction. PCR 
reactions were performed by using approximately 100 ng 3°C template.  
Tgm2 -20kb (BAIT)                                                               
Fw: 5’- CACACACACATACGGTTCTGTT -3’ 
Tgm2 +11kb                                                      
Fw: 5’- CAGTCCTAGGGAAGTGGAGC -3’ 
Tgm2 +13kb                       
Fw: 5’- TTATGGGTTTGGGGACTGCA -3’ 
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Tgm2 +30kb                                                                          
Fw: 5’- GGCAGACCTTGTTTGAATGTGA -3’ 
Loading control primers (chr10:74788584-74788803): 
Fw: 5’ - CTC CAC CAT GAT GTA CAC CG – 3’                                                     
Rev: 5’- CATGGTTTCGGGAGATGCAG - 3’ 
 
2.9. Statistical analysis 
All data are presented as means +/-SD. We made three biological replicates in all the 
experiments and we performed paired (two tailed) t tests. Results were considered significant 
with p< 0.05.  
 
3. Results 
 
3.1.Combination of DNase-seq and ChIP-seq allows identification of the putative 
enhancer set of Tgm2 
 
To identify the putative enhancer elements, which might play a role in the regulation of Tgm2 
in mouse thymocytes, we exploited several mouse thymus derived datasets generated by the 
ENCODE Consortium. As a very first step, we tried to exploit the recently described feature 
about the motif orientation of CTCF and its effect on long-range chromatin looping and 
demarcating functionally different genomic regions. Tandem orientation of the CTCF motifs 
has been proposed to play role in gene regulation by allowing the enhancers to find their 
targets, while convergent motifs are more likely to be implicated in the formation of higher-
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order chromatin structure [27,28]. We found three high affinity CTCF peaks flanking a 157kb 
wide genomic region around Tgm2 (Fig. 1A). Analysis of the orientation of the motifs showed 
one convergent motif pair located at the borders of the 157kb genomic area, while the third, 
transcription start site (TSS) specific motif constitutes a tandem motif pair with the upstream 
CTCF border (Fig. 1A). These data suggest that the regulation of the gene might take place in 
a genomic region spanning 157 kb pairs. While convergent motifs are likely to function in 
establishing topologically associated domain borders, there are still many exceptions in which 
case potential enhancers could be overlooked. To avoid this possibility, we overlapped the 
interaction profile of a genomic loci of ~800kbp containing the Tgm2 locus with the available 
CTCF ChIP-seq and DNase-seq from the CH12.LX mouse B lymphoblast cells [27] and the 
same datasets from thymus along with the histone modification ChIP-seq profiles. We found 
that interactions between the two proposed boundaries are clearly enriched suggesting that the 
regulation of Tgm2 most probably takes place in this genomic unit and the enhancers do not 
communicate with the neighboring genes (Supplementary Figure 2). In addition, we also 
measured the mRNA expression of the neighboring gene (Rprd1b, chr2:157854530-
157903056), which seems to be active based on the H3K4me3 histone modification present at 
the transcription start site of the gene. However, we could not detect any difference in its 
expression level in the presence of those compounds [7-9], which affected the expression 
Tgm2 (data not shown). 
Next we took advantage of the available DNase-seq dataset and identified several 
hypersensitive sites around the Tgm2 gene located between the tandem CTCF sites, and an 
additional one located between the TSS specific and the downstream CTCF site, which show 
convergent motif orientation (Fig.1A). Since integration of DNase-seq with ChIP-seq against 
H3K4me3, H3K4me1 and H3K27ac proved to be useful in the identification of putative 
functional enhancers [15-17], [35], we applied this approach to find six (+30kb, TSS, -7.9kb, -
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13kb, -20kb, -28kb) hypersensitive regions which showed enrichment for H3K4me3 and for 
H3K4me1. H3K4me3 is a hallmark of actively transcribed protein coding gene promoters 
[14], but can be detected occasionally together with enhancers due to a strong 
enhancer/promoter interaction. H3K4me1 is associated with most of the accessible regulatory 
elements in the genome and represents active, poised or primed enhancers depending on the 
presence of other histone modifications [15-16]. Out of the six elements, only two (-13kb and 
-20kb) showed enrichment for H3K27ac, which is a widely accepted functionally active 
enhancer marker [16]. Thus using the ENCODE generated genome-wide datasets from mouse 
thymus we have identified five intergenic enhancers for detailed analysis excluding the 
TSS/promoter region, which has been studied thoroughly. 
 
3.2.The acetylation levels of the putative enhancers of Tgm2 from the whole thymus 
tissue and from in vitro cultured thymocytes show similar pattern  
 
The thymus is composed of various types of cells. Although thymocytes constitute the 
majority of cells in the thymus [36], one should be careful of using whole thymus for 
enhancer mapping, because other cell types, such as macrophages, dendritic cells and 
epithelial cells are also present. Therefore, signals are not reliably originated from the cell 
type of interest. That is why we isolated thymocytes from the mouse thymus to check whether 
the selected putative enhancers of Tgm2 in these cells show a similar pattern of H3K27ac. As 
shown in Figure 1B, our ChIP-qPCR experiments demonstrated that similar to the ENCODE 
data originated from the whole thymus (Fig.1A), in in vitro cultured thymocytes the two (-
13kb and -20kb) enhancer elements are much stronger acetylated as compared to the other 
putative enhancers of Tgm2 (Fig. 1B). In accordance we found that these two highly 
acetylated enhancers have a concomitant enrichment also for the two well-known histone 
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acetyltransferases P300 and CBP. These results proved the adaptability of the two systems 
showing positive correlation between the whole thymus derived genome-wide datasets and 
our ChIP experiments on individual enhancers from thymocytes cultured in vitro.   
 
 
3.3.Enhancer RNA measurements identify functional enhancers for the Tgm2 gene 
 
Previous studies from our laboratory have shown that in thymocytes TGM2 expression is 
regulated by external signals derived from engulfing macrophages, such as retinoids [7], 
TGF-and adenosine, the latter activating adenosine A2A receptors and the consequent 
adenylate cyclase pathway [9]. Among these signals 9cRA was the most effective in inducing 
TGM2 mRNA levels, resulting in a 5 fold induction. Activation of both the adenylate cyclase 
and the TGF-signaling pathway synergized with the retinoid signaling pathway in inducing 
TGM2 mRNA levels.          
 To determine whether the putative enhancers respond to these signals, we decided to 
measure the amount of eRNAs transcribed from them. To detect the response of the individual 
enhancers, primary thymocytes cultured in vitro were exposed for 1 h to 0.3 M 9cRA, a 
ligand of the nuclear retinoic acid receptors (RAR/RXR) [37], to 5 ng/ml rTGF- leading to 
trimerization of SMAD4 with phosphorylated SMAD2 or 3 and its nuclear transport [36], or 
to 100 M dbcAMP, a membrane permeable analogue of cAMP, resulting in the activation of 
protein kinase A and in subsequent phosphorylation of CREB [39]. However, phosphorylation 
and activation of CREB can occur also via activation of both the TGF- signaling 
pathwaywhich activates protein kinase A in a cAMP-independent manner leading to the 
release of its regulatory subunit [40] and the retinoid signaling pathway, which can lead  to 
18 
 
CREB phosphorylation in a protein kinase A-dependent [41,42] and independent [43,44] 
manner. 
Interestingly, all of the enhancers showed elevated eRNA expression in response to 9-
cRA, but only two of them, located  -13kb and -20kb, appeared to be regulated also by TGF- 
or dbcAMP (Fig. 2A, B). In addition, these two enhancers showed clear differences in their 
retinoid response showing a much robust eRNA upregulation as compared to the +30kb, -
7.9kb and -28kb enhancers.         
 Our knowledge about these signaling pathways allowed the investigation of the 
binding of the signal specific transcription factors on these enhancers. We applied ChIP-qPCR 
to measure the enrichment of CREB, SMAD4, RAR and RXR in the presence of their 
activators on the identified enhancer elements (Fig. 2C). Exposure to dbcAMP efficiently 
recruited CREB to each enhancer elements, but the occupancy of CREB appeared to be the 
highest when we tested its binding on enhancers located at -13kb and -20kb. In accordance 
with reports, which demonstrated CREB activation in the retinoid and TGF-signaling 
pathways, enhanced CREB binding could be detected also following exposure to 9cRA or 
rTGF-, but again the occupancy of CREB appeared to be the highest when we tested its 
binding on the enhancers located at -13kb and -20kb (Fig. 2C).  Similarly, when we assessed 
the binding of SMAD4 in the presence of rTGF-, we found a similar pattern of dynamic 
recruitment on the investigated enhancers with the exception of the -7.9kb and -28kb 
enhancers which did not show any enrichment. ChIP-qPCR experiments performed against 
RAR or RXR in the presence of 9cRA did not show robust recruitment on the investigated 
enhancers. Still, an enhanced binding of RAR and RXR, as a 9cRA response, was found on 
all the investigated enhancers. In line with the eRNA measurements, these results indicate that 
the majority of RARs and RXRs are already bound to all of the investigated sites even in the 
absence of the externally added agonist, as it was previously shown by others [45], [24].  In 
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our negative control experiments, in which we performed the same experiments on the 
neuronal specific Prmt8 gene -1.7kb region, neither eRNA formation, nor transcription factor 
bindings were found (Supplementary figure 3).       
 Our results demonstrate that the strategy developed by us proved to be efficient in the 
identification of signal selective enhancers. By measuring the synthesized eRNA species from 
individual enhancers and combining the results with transcription factor binding data, we 
identified five signal selective enhancers of Tgm2 in mouse thymocytes.  
 
3.4. The signaling pathway induced by TGF- selectively potentiates the retinoid 
signaling on Tgm2 associated enhancer elements 
 
Recently, it has been shown by our group that the adenylate cyclase and TGF-mediated 
signaling synergize with the retinoid signaling on TGM2 leading to a more pronounced 
induction of TGM2 at protein level [7]. In line with the protein data, we found by using qRT-
PCR analysis that administration of TGF- could significantly increase the 9cRA-induced 
mRNA expression of Tgm2 (Fig.3A). Based on these results we decided to test, whether the 
activation of TGF-signaling could potentiate the retinoid-mediated signaling pathways in 
the context of Tgm2 regulation. To identify those enhancers on which the collaboration 
between the two signaling pathways might take place, we determined enhancer specific eRNA 
levels in the presence of various signal combinations. As shown in Figure 3B, enhancer 
elements located at +30kb and at -28kb did not show any sign of collaboration in agreement 
with our previous results, which indicated that on these elements no significant TGF--
induced SMAD4 binding was found. On the other hand, we could detect significantly 
increased eRNA expression on the -7.9kb, -13kb and -20kb enhancers if both signals were 
present, indicating that the TGF-and the retinoid pathways crosstalk on these enhancers. To 
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analyze this crosstalk in more detail, we performed ChIP-qPCR experiments using RXR 
specific antibodies. While 9-cRA alone resulted only in a slight increase in the RXR 
recruitment, a significant increase in the recruitment of RXR to the enhancers located -7.9kb, 
-13kb and -20kb could be detected, when TGF-was also administered (Fig. 3C). 
Interestingly, in the presence of both signals the SMAD4 recruitment increased also. 
Moreover, the recruited P300 and CBP showed also elevated levels on these enhancer 
elements in response to TGF-/9cRA co-treatment as compared to 9cis-RA alone. These 
results suggest that in the presence of both signals the accessibility of these sites increases for 
both transcription factors, which ultimately leads to an increased coactivator binding and 
more efficient transcription. Interestingly, in the case of the -7.9 kb enhancer the interaction 
existed between the two pathways despite the lack of significant binding of SMAD4 to this 
enhancer in the presence of TGF-alone.      
 Knowing the fact that 9cRA is able to activate various RXR heterodimers including 
RAR/RXR, we applied a selective synthetic agonist of RARα (AM580) and that of RXR 
(LG268) to determine the target of interaction between the retinoid and the TGF-signaling 
pathways on the signal integrator enhancers (-13kb and -20kb). We found that both the RARα 
and the RXR activator alone could significantly induce the level of enhancer transcripts at the 
signal integrator enhancers. Interestingly, when we measured the activation of these enhancers 
in the presence of the signal combinations of TGF-/AM580 or TGF-/LG268, we found a 
more pronounced eRNA expression in both cases and on both enhancers (Fig. 3D). These data 
indicate that TGF- signaling is able to potentiate the transcriptional activity of the 
RXR/RAR heterodimer, in line with the fact that we detected both RAR and RXR binding 
on these enhancers. In addition, administration of the pan RAR antagonist AGN194310 
reduced LG268/TGF--induced eRNA levels to the TGF-AGN194310-induced eRNA 
levels, and the AM580/TGF--and the LG268/TGF--induced eRNA levels to that of the 
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AM580/AGN194310-and the LG268/AGN194310-induced eRNA levels, respectively, 
indicating that only RAR/RXR heterodimers interact with the TGF-signaling on these 
enhancers. 
 
3.5. The adenylate cyclase pathway also selectively potentiates retinoid signaling on 
Tgm2 associated enhancer elements 
 
Since previous studies indicated that the adenylate cyclase pathway also enhances TGM2 
protein levels in the thymocytes in vivo [9], we determined Tgm2 mRNA levels in the 
presence of dbcAMP as well. As shown in Figure 4A exposure to dbcAMP alone enhanced 
the steady state levels of Tgm2 mRNA, and when dbcAMP was applied together with 9cRA, 
it synergized with retinoid signaling in regulating Tgm2 mRNA levels, though less efficiently 
as TGF-did (Fig. 3A). Next by measuring eRNA levels on the various enhancers, we 
examined whether the two signaling pathways synergize also in the context of Tgm2 
regulation. As shown in Figure 4B, enhancer elements located at +30kb, -7.9kb and -28kb did 
not show any sign of collaboration in agreement with our previous results, which indicated 
that on these elements no significant dbcAMP-induced CREB binding was found. On the 
other hand, we could detect significantly increased eRNA expression on the -13kb and -20kb 
enhancers if both signals were present, indicating that the adenylate cyclase and the retinoid 
signaling pathways crosstalk on these enhancers.       
 To analyze this crosstalk in more detail, we performed similar ChIP-qPCR 
experiments for transcription factor binding, as we did for studying the TGF-/retinoid 
signaling crosstalk. However, as seen in Figure 4C, exposure to dbcAMP did not enhance the 
9cRA-induced RXR recruitment to any of the enhancers. The recruitment of CREB, on the 
other hand, on most enhancers was higher in the presence of the two signals, than in the 
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presence of 9cRA alone, but not higher than in the presence of dbcAMP alone. Thus, while in 
the case of the TGF-/retinoid crosstalk we detected increased enhancer accessibility for 
RXR, when the two signals were present together, no such an enhancement for RXR binding 
was detected in the adenylate cyclase/retinoid signaling crosstalk. In addition, despite the fact 
that more CREB was recruited to most of the enhancers in the presence of the two signals, 
neither more CBP, nor more P300 coactivator binding were detected in the presence of 
dbcAMP, as compared to 9cRA alone. 
 
3.6.Chromosome conformation capture experiments reveal interactions between the 
-20kb enhancer and the Tgm2 gene 
 
As a control for our approach, we performed chromosome conformation capture experiments 
[33,34] to prove that the enhancers, we identified, interact with Tgm2 gene. For this purpose 
we selected the +11kb and the +30 kb (-3’ UTR) regions of the gene, which are DNase 
hypersensitive and as a control the +13kb region, which is a lowly accessible region. The 
limitation of the method related to the HindIII restriction sites allowed us to investigate the 
interaction of these regions with the potential -20kb enhancer. As shown in Figure 5, we were 
able to demonstrate the interaction between the enhancer located -20kb and the intronic region 
of the gene. Interestingly, we also found an interaction with the 3’ UTR of the gene, where we 
also identified a DNase hypersensitive site, but could not show the interaction with the 
intervening sequence (+13kb region). Importantly, none of these contacts appeared to show 
induced interactions in the presence of the applied agonists, indicating that these are stable, 
pre-formed loops between the enhancer and the gene.  
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4. Discussion 
 
Previous studies from our laboratory have shown that the expression of the TGM2 protein is 
associated with the in vivo apoptosis of thymocytes and is regulated transcriptionally by at 
least three extracellular signals arriving from the neighboring engulfing macrophages [6-9].  
However, the regulation of TGM2 expression must be very complex, since the protein is 
ubiquitously expressed and participates in many biological processes [2]. During the years 
several publications appeared in the literature about the regulation of the Tgm2 gene [10-13]. 
However, these studies were limited to the investigation of one single promoter element, and 
did not address the cell type specific transcriptional regulation of the gene. With the help of 
the next-generation sequencing coupled approaches we had the opportunity to specifically 
map and identify the cell type- and gene-specific regulatory elements genome-wide as shown 
by others [14-18]. In the present study, we took advantage of the ENCODE generated datasets 
from mouse thymus. Using the integration of DNase-seq and ChIP-seq approaches we 
revealed the putative regulatory element repertoire of Tgm2. We have exploited the recently 
described phenomenon about CTCF motif orientation [27,28] in order to find the most 
probable, functional enhancer set for Tgm2. These approaches lead to the identification of five 
intergenic elements (+30kb, -7.9kb, -13kb, -20kb, -28kb) as potential regulators of the gene in 
dying thymocytes.  The functional contribution of these elements to transcription regulation 
could be studied with the well-known, though sometimes artificial luciferase based reporter 
assays. However, if the cell type of interest is not a good subject for modification, such as the 
fast dying thymocytes, it is almost impossible to get reliable information about the function of 
a given enhancer element under the cell type specific setting. Several studies have recently 
described that activation of a signal specific transcription factor leads to a similar induction 
profile on the target genes as on the contributing enhancer elements at the nascent RNA level 
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[20,23,24]. As a result, eRNA production from an enhancer has been accepted as one if not 
the best marker for enhancer activation [22]. Although, their function in transcription 
regulation is debated, more and more studies report eRNA specific functions in gene 
regulation [46-48]. In addition, the presence of eRNAs is indicative of loop formation 
between the enhancer and gene promoter. Thus, as a novel possible tool, so far not applied for 
clarification of the functional contribution of the individual enhancer elements to the 
regulation of a gene, we decided to determine the production of eRNAs [19] synthesized from 
active enhancers of the Tgm2 gene in the presence of TGF-dbcAMP or retinoids. These 
measurements revealed three retinoid selective enhancers located +30kb, -7.9kb and -28kb 
respectively. Surprisingly, we found two distant enhancer elements located at -13kb and -
20kb away from the gene, at which we detected eRNA transcription in response to all of the 
above mentioned activators. Actually, these two regions show the highest DNase 
hypersensitive profile in agreement with their histone acetylation level, histone 
acetyltransferase enrichment determined by the presence of P300 and CBP, and the 
occupancy of the signal specific transcription factors in response to stimulation. In addition, 
combinations of 9cRA with dbcAMP or TGF- showed a potentiated retinoid response on 
these enhancers. Furthermore, we were also able to show that the more distant -20kb enhancer 
interacts with the intronic- and 3’UTR-region of the gene using 3C approach. These data 
indicate that these enhancers might act as integrators, and might function also as shadow 
enhancers [49] in the regulation of the Tgm2 gene expression.    
 In the case of TGF-and retinoid synergism the enhanced eRNA transcription at these 
sites was attributable to more RXR, SMAD4, P300 and CBP recruitment in the presence of 
the two signals. Interestingly, though we detected a crosstalk between the adenylate cyclase 
and retinoid signaling pathways as well, this latter interaction did not result in enhanced CBP 
or P300 binding, despite the fact that an enhanced CREB binding was also detected. However, 
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CREB works in concert not only with the coactivator CBP, but depending on the cellular 
context, also with a family of coactivators called CREB-regulated transcription coactivators 
(CRTCs) [50]. Of the CRTC family members, CRTC2 is thought to be the major mediator of 
regulated CREB target gene expression [51] and is known to be expressed by T cells as well 
[52].  Alternatively, the adenylate cyclase signaling pathway regulates these enhancers via 
other transcription factors as well and not only via CREB. Since in the ENCODE database we 
have not found ChIP-seq datasets for transcription factor bindings related to mouse thymus, 
we decided to check the motifs under the identified DNase hypersensitive regions using the 
JASPAR database. We probed all the regulatory sites for the motifs of the following 
transcription factors known to be regulated by the adenylate cyclase signaling pathway: 
CREB1, CCAAT/enhancer-binding protein alpha (CEBPA), activating transcription factor 1 
(Atf1), Atf3, Creb3l2, cAMP response element modulator (Crem), CREB3, CEBPB, CEBPD, 
CEBPE, CEBPG, CREB3L1, Creb5. Interestingly, many of these transcription factor binding 
motifs are enriched under the identified regulatory regions (Supplementary Table 1). The two 
cAMP-responsive elements showed enrichment for these motifs also, but we found only 
CREB1 motif at the enhancer located -20kb from the gene. This prediction validated our 
approach because we found the strongest CREB binding at this sites using ChIP-qPCR. At the 
-13kb enhancer we found several CREB1 motifs and also other CREB motifs, but importantly 
ATF motifs were also enriched. Thus the crosstalk between the adenylate cyclase and the 
retinoid signaling pathways might be mediated via proteins that we did not investigate in our 
study.            
 In summary, in the present study, we dissected the regulation of an apoptosis related 
gene in mouse thymocytes in a so far unprecedented manner. Our strategy to map and study 
the contribution of individual enhancers in the regulation of Tgm2 serves as a proof of 
concept, thus can be applied to solve similar problems. However, we would like to emphasize 
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that the usage of genome engineering is inevitable in order to support direct evidence about 
the contribution of a single enhancer element in gene regulation.  Our results shed light on a 
very intriguing regulatory process at the level of individual enhancers and show that such 
enhancer clusters are able to integrate various signaling pathways, as it has been proposed 
recently by the super-enhancer concept [51]. This theory suggests that members of the super-
enhancers can physically and functionally interact with each other in order to fine tune the 
activity of the target gene. We think that the enhancers of Tgm2 in thymocytes serve a similar 
function by enabling the dying cells to respond very precisely to the environmental signals in 
the thymus. Among these signals macrophage-derived TGF-has been shown to contribute 
also to the differentiation of regulatory T cells which, as a result, depends on the constantly 
ongoing apoptosis and engulfment of the improperly produced thymocytes in the thymus after 
birth [52]. 
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Figure Legends 
Figure 1 Finding putative enhancers for the Tgm2 gene in mouse thymocytes. (A) IGV 
genome browser view about the Tgm2 locus. ChIP-seq results against CTCF, H3K4me1, 
H3Kme3 and H3K27ac along with the DNase hypersensitive sites are shown from mouse 
thymus. CTCF motif orientations are indicated with black horizontal arrows and the 
presumable interactions are depicted as connecting lines between them (top). Intergenic 
DNase hypersensitive sites and the TSS of Tgm2 are shown with vertical arrows, and their 
relative distance to the TSS is also highlighted (under the CTCF track). TSSs of Tgm2 and 
Rprd1b genes are also shown with the direction of the gene highlighted by horizontal arrows. 
(B) ChIP-qPCR measurements against CBP, P300 and H3K27ac from in vitro cultured mouse 
thymocytes are shown on the indicated intergenic regulatory elements. As a control, we also 
performed the same ChIP-qPCRs on the neuron specific Prmt8 gene -17kb region, which in 
the thymic genome appears as a non-DNase hypersensitive region (non-DHS). Data represent 
mean±SD of triplicate measurements. 
 
Figure 2 Combined eRNA measurements and determination of transcription factor binding 
identify functional enhancers for the Tgm2 gene. (A) Tgm2 mRNA levels determined by RT-
qPCR analysis in the presence of the indicated compounds (0.3 M 9cRA, 5 ng/ml rTGF- or 
100 M dbcAMP). (B) Intergenic DNase hypersensitive sites and their relative distance to the 
TSS of Tgm2 are shown (top). (C) Enhancer RNA levels determined by RT-qPCR analysis on 
the indicated Tgm2 enhancers in the presence of the indicated molecules (0.3 M 9cRA, 5 
ng/ml rTGF- or to 100 M dbcAMP) in in vitro cultured thymocytes after 1 h treatment. (D) 
CREB, SMAD4, RXR and RAR binding on the indicated enhancer elements determined by 
ChIP-qPCR analysis in the presence of the indicated molecules after 1 h exposure. 
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Background was determined by using rabbit IgG and subtracted from the values presented on 
the graphs. CTR: vehicle treated control. As a negative control, we also performed the same 
eRNA and ChIP-qPCR measurements on the neuron specific Prmt8 gene -17kb region, which 
in the thymic genome appears as a non-DNase hypersensitive region (Supplementary Figure 
3). Data represent mean±SD of triplicate determinations. *Significantly different (P<0.05). 
Figure 3 The signaling pathway induced by TGF- selectively potentiates the retinoid 
signaling on Tgm2 associated enhancer elements.  (A) Tgm2 mRNA levels determined by RT-
qPCR analysis in the presence of the indicated compounds (0.3 M 9cRA, 5 ng/ml rTGF- or 
0.3 M 9cRA/5 ng/ml rTGF-) after 6 h treatment. mRNA levels are expressed as fold 
induction as compared to the DMSO (0.5%) exposed samples. (B) Enhancer RNA levels 
determined by RT-qPCR analysis on the indicated Tgm2 enhancers in the presence of the 
indicated molecules in in vitro cultured thymocytes after 1 h treatment. (C) RXR, SMAD4, 
P300 and CBP binding on the indicated enhancer elements determined by ChIP-qPCR 
analysis in the presence of the indicated compounds after 1 h treatment. Background was 
determined by using rabbit IgG and subtracted from the values presented on the graphs. (D) 
Enhancer RNA levels determined by RT-qPCR analysis on the indicated Tgm2 enhancers in 
the presence of  1 M AM580, an RAR agonist, nM  LG268, an RXR agonist, 5 ng/ml 
rTGF-, 100 nM AGN194310, a pan RAR agonist  in in vitro cultured thymocytes after 1 h 
treatment. CTR: vehicle treated control. As a negative control, we also performed the same 
eRNA and ChIP-qPCR measurements on the neuron specific Prmt8 gene -17kb region, which 
in the thymic genome appears as a non-DNase hypersensitive region (Supplementary Figure 
3). Data represent mean±SD of triplicate determinations. *Significantly different (P<0.05). 
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Figure 4 The adenylate cyclase pathway also selectively potentiates retinoid signaling on 
Tgm2 associated enhancer elements. (A) Tgm2 mRNA levels determined by RT-qPCR 
analysis in the presence of the indicated compounds (0.3 M 9cRA, 100 M dbcAMP or 0.3 
M 9cRA/100 M dbcAMP)  after 6 h treatment. mRNA levels are expressed as fold 
induction as compared to the DMSO (0.5%) exposed samples. (B) Enhancer RNA levels 
determined by RT-qPCR analysis on the indicated Tgm2 enhancers in the presence of the 
indicated molecules in in vitro cultured thymocytes after 1 h treatment.(C) RXR, CREB, P300 
and CBP binding on the indicated enhancer elements determined by ChIP-qPCR analysis in 
the presence of the indicated compounds after 1 h treatment. Background was determined by 
using rabbit IgG and subtracted from the values presented on the graphs. CTR: vehicle treated 
control. As a negative control, we also performed the same eRNA and ChIP-qPCR 
measurements on the neuron specific Prmt8 gene, which in the thymic genome appears as a 
non-DNase hypersensitive region (Supplementary Figure 3). Data are represented as mean± 
SD of triplicate determinations. *Significantly different (P<0.05). 
 
Figure 5 Chromosome Conformation Capture (3C) experiments reveal interactions between 
the -20kb enhancer and the intronic-, 3’UTR region of the Tgm2 gene. (A) IGV genome 
browser representation of DNase hypersensitive regions on the Tgm2 locus in mouse 
thymocytes. HindIII cutting sites are indicated all over the locus, along with the used 
restriction fragments for 3C analysis. BAIT represents the starting point of the analysis 
overlapping with the -20kb enhancer. (B) Gel (1.5% agarose) image of 3C-PCR products 
combining BAIT-specific with the +11kb-, +13kb-, +30kb-specific primers. Thymocytes were 
treated with the indicated compounds for 1 h before fixation. No ligase controls are also 
carried out and indicated (middle). Gel image (1.5% agarose) of PCR products using primers 
specific to chr10:74788584-74788803 genomic region as a loading control (bottom). 
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Supplementary figure 1 Finding the position in the DNA to which primers are designed to 
detect eRNA transcription from a putative enhancer. 
Supplementary figure 2 Integration of Hi-C interaction data, CTCF ChIP-seq and DNase-
seq from CH12.LX cells along with mouse thymocyte data for DNase-seq and ChIP-seq 
against CTCF, H3K4me1, H3K4me3 and H3K27ac. Contact matrix heatmap was generated 
using the Interactive Hi-C Data Browser available at http://www.3dgenome.org. Hi-C data 
was generated by Rao et al. from the CH12.LX mouse B lymphoblast cell line. Data is shown 
with 5kb resolution on the indicated genomic region (top). IGV browser representation of 
ChIP-seq and DNase-seq experiments from the indicated cell types. CH12.LX-derived 
datasets are available under accessions: GEO:GSM912909 (CTCF ChIP-seq), 
GEO:GSM1014153 (DNase-seq) The Tgm2 locus is marked with dashed lines and the motif 
direction of the two CTCF anchors (black arrows) are also shown used by us to predict the 
functional domain of the gene in which the regulation might take place (bottom). 
 
Supplementary figure 3 Enhancer RNA levels and RXR, SMAD4, P300, CBP and CREB 
binding to an enhancer of the neuron specific Prmt8 gene, -1.7 kb far from the TSS region. 
(A) Enhancer RNA levels determined by RT-qPCR analysis on the Prmt8 -1.7 kb region in 
the presence of the indicated molecules in in vitro cultured thymocytes after 1 h treatment. (B) 
RXR, SMAD4, P300, CBP and CREB binding on the Prmt8 -1.7 kb region determined by 
ChIP-qPCR analysis in the presence of the indicated compounds after 1 h treatment. 
Background was determined by using rabbit IgG and subtracted from the values presented on 
the graphs. Compounds used were: 0.3 M 9cRA, 5 ng/ml rTGF-, 100 M dbcAMP, 1 M 
AM580, nM LG268, 100 nM AGN194310. CTR: vehicle treated control. Data represent 
mean±SD of triplicate determinations. 
